William Blair Forecasts Agenus’ Q1 Earnings (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN) – Investment analysts at William Blair boosted their Q1 2025 earnings per share (EPS) estimates for Agenus in a research report issued to clients and investors on Tuesday, March 11th. William Blair analyst M. Phipps now anticipates that the biotechnology company will post earnings per share of ($1.17) for the quarter, up from their prior estimate of ($1.31). The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. William Blair also issued estimates for Agenus’ Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($3.48) EPS, FY2026 earnings at ($2.58) EPS and FY2027 earnings at ($2.51) EPS.

Agenus (NASDAQ:AGEN) last issued its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.36) by $0.32. The firm had revenue of $26.84 million during the quarter, compared to analyst estimates of $30.09 million.

A number of other brokerages have also recently commented on AGEN. Robert W. Baird reduced their price objective on Agenus from $6.00 to $3.00 and set a “neutral” rating on the stock in a research note on Wednesday. HC Wainwright restated a “neutral” rating on shares of Agenus in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.75.

Agenus Price Performance

Shares of AGEN opened at $1.86 on Friday. The stock’s 50-day moving average is $3.17 and its two-hundred day moving average is $3.78. The stock has a market cap of $43.63 million, a PE ratio of -0.17 and a beta of 1.23. Agenus has a 12 month low of $1.65 and a 12 month high of $19.69.

Institutional Trading of Agenus

Hedge funds and other institutional investors have recently modified their holdings of the business. EP Wealth Advisors LLC purchased a new stake in shares of Agenus during the third quarter worth about $55,000. Corton Capital Inc. bought a new stake in Agenus in the fourth quarter valued at about $36,000. Point72 DIFC Ltd increased its holdings in Agenus by 380.0% in the third quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 11,542 shares during the last quarter. Virtu Financial LLC bought a new stake in Agenus in the fourth quarter valued at about $51,000. Finally, Apollon Wealth Management LLC bought a new stake in Agenus in the fourth quarter valued at about $55,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.